ATXN1

ATXN1 Full Name

ataxin 1

ATXN1 Introduction

ATXN1 (ataxin 1) is a predominantly nuclear protein that functions as a transcriptional regulator involved in the development and maintenance of the nervous system. The gene is located on chromosome 6p22.3 and encodes a protein of 815 amino acids with a molecular weight of approximately 87 kDa. ATXN1 is widely expressed in human tissues, with particularly high levels in the brain, especially in the cerebellum, cerebral cortex, and hippocampus. The protein contains a conserved AXH (ataxin-1 and HBP1) domain that mediates protein-protein interactions and transcriptional repression, as well as a polyglutamine (polyQ) tract near the N-terminus. In healthy individuals, the polyQ tract contains 6 to 39 glutamine residues. However, expansion of this tract to 40 or more glutamines causes spinocerebellar ataxia type 1 (SCA1), an autosomal dominant neurodegenerative disorder characterized by progressive ataxia, dysarthria, dysphagia, and cognitive impairment. The expanded polyQ tract confers a toxic gain-of-function property to ATXN1, leading to protein misfolding, aggregation, and neuronal dysfunction and death. Beyond SCA1, ATXN1 has been implicated in other neurological disorders including autism spectrum disorder (ASD) and cancer, reflecting its broader roles in transcriptional regulation and cellular homeostasis.

Figure 1. Schematic structure of ATXN1.

Core Physiological Functions of ATXN1
ATXN1 executes indispensable physiological functions in neural development, transcriptional homeostasis, and cellular stress regulation to maintain central nervous system stability and normal tissue function. During embryonic and postnatal brain development, ATXN1 modulates neuronal progenitor cell proliferation, differentiation, and maturation, supporting the formation and structural integrity of cerebellar and cortical neural circuits. In mature neurons, wild-type ATXN1 localizes primarily in the nucleus to fine-tune the transcription of neuronal survival genes, synaptic function-related genes, and neurodevelopmental regulators, sustaining normal neuronal excitability and neural signal transmission. ATXN1 also participates in cellular stress response and protein quality control, assisting in the clearance of misfolded proteins and maintaining intracellular proteostasis under physiological conditions. Furthermore, ATXN1 regulates cell cycle progression and cellular senescence in non-neuronal tissues, balancing cell renewal and tissue aging to preserve systemic tissue homeostasis and organ function stability.

Clinical Significance: Spinocerebellar Ataxia Type 1 and Neurodegeneration
Expansion of the polyglutamine tract in ATXN1 to 40 or more repeats causes spinocerebellar ataxia type 1, an autosomal dominant neurodegenerative disorder with onset typically in the third to fifth decade of life. The length of the polyQ expansion correlates inversely with age of onset; longer repeats cause earlier and more severe disease. SCA1 is characterized by progressive ataxia (loss of coordination) due to degeneration of cerebellar Purkinje cells and brainstem neurons, as well as dysarthria (slurred speech), dysphagia (difficulty swallowing), cognitive impairment, muscle weakness, and eventually respiratory failure, which is the most common cause of death. The pathogenic mechanism of SCA1 is a toxic gain-of-function: the expanded polyQ tract promotes ATXN1 misfolding and aggregation into nuclear inclusions (intranuclear bodies) in affected neurons. However, aggregation is not the sole mechanism; the expanded polyQ tract also enhances the stability of ATXN1 (normally a short-lived protein) by impairing its ubiquitination and degradation, leading to accumulation of ATXN1 protein. Accumulated ATXN1 retains its interaction with CIC but exhibits altered transcriptional activity, leading to dysregulation of CIC target genes. The presence of the phosphorylation site at Ser-776 (S776) is essential for ATXN1 toxicity; mutation of S776 to alanine (S776A) prevents toxicity in animal models. Other post-translational modifications, including ubiquitination at Lys-207, sumoylation at Lys-194 and Lys-754, and acetylation at Lys-541, also modulate ATXN1 stability and toxicity. Beyond SCA1, intermediate-length polyQ expansions (typically 30-39 repeats) have been associated with an increased risk of autism spectrum disorder (ASD) in some studies. Rare missense mutations in ATXN1 have also been identified in individuals with ASD and other neurodevelopmental disorders, suggesting broader roles in neuropsychiatric disease.

Alternate Names for ATXN1

ATXN1; ataxin 1; ATX1; SCA1; D6S504E; ataxin-1; alternative ataxin1; spinocerebellar ataxia type 1 protein;